Clinical Trials Arena on MSN3d
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase IIIUK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...
The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the ...
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
Topline data were announced from a phase 3 trial evaluating eneboparatide in adults with chronic hypoparathyroidism.
In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral ...
Alexion Pharmaceuticals’ ravulizumab for the prevention of delayed graft function after renal transplantation was granted FDA orphan ...
High-level results from the CALYPSO Phase III trial showed that eneboparatide, AZP-3601, an investigational parathyroid hormone receptor 1 ...
The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab ( ...
LONDON, UK I March 17, 2025 I High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary ...
AstraZeneca added eneboparatide to the Alexion and AstraZeneca rare disease pipeline through the acquisition of Amolyt Pharma in July 2024, in a deal valued around $1.05bn. Shareholders received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback